((自动化翻译由路透提供，请见免责声明 ))
路透10月10日 - 辉瑞 周四称，在一项晚期研究中，其药物Talzenna和Xtandi的组合有助于延长一种晚期前列腺癌患者的生命。
辉瑞公司说，与Xtandi单药相比，这种联合用药在转移性抗性前列腺癌(mCRPC) 患者的总生存期方面有明显改善，无论是否存在基因突变。
总生存期是指患者在确诊或开始治疗后的生存时间。
mCRPC是一种癌症已扩散到身体其他部位的晚期疾病，通常预后较差。据辉瑞公司称，约有10%-20%的前列腺癌患者会在确诊后5到7年内患上mCRPC。
Talzenna-Xtandi组合去年获得美国食品药品管理局批准 (link)，用于治疗有一种基因突变的mCRPC患者。
辉瑞表示，它计划与全球卫生机构分享研究结果，以便更新Talzenna的标签。
美国食品和药物管理局去年还批准了 (link) 阿斯利康公司的Lynparza与激素疗法阿比特龙联用，治疗有一种基因突变的mCRPC患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.